Department of Endocrinology, University College Hospital London, NW1 2BU, UK.
Department of Investigative Medicine, Imperial College London, Hammersmith Hospital, London, W12 0NN, UK.
Best Pract Res Clin Endocrinol Metab. 2022 Sep;36(5):101617. doi: 10.1016/j.beem.2022.101617. Epub 2022 Jan 21.
Androgen therapy is the mainstay of treatment in female to male (FtM) transgender persons to increase testosterone levels, suppress oestrogens and treat gender dysphoria. Testosterone is widely used for male hypogonadism, but is comparatively under-investigated in FtM transgender persons. The aim of our study was to identify treatment and safety outcomes associated with testosterone use in transgender medicine. Androgens in FtM transgender persons are effective to lower voice frequency, increase facial hair-growth, and increase hematocrit and hemoglobin levels to adult male reference ranges. A 1.2-fold-3.7-fold higher rate of myocardial infarction has been reported retrospectively, compared to cisgender women. Blood pressure, glycaemic control and body mass index remained unchanged in FtM transgender persons. Androgens in FtM transgender persons have important cardio-metabolic implications. Randomised control trials, longer follow-up periods and studies involving older persons may further improve the management of FtM transgender persons.
雄激素治疗是女性向男性（FtM）跨性别者的主要治疗方法，目的是增加睾酮水平、抑制雌激素并治疗性别焦虑。睾酮广泛用于男性性腺功能减退症，但在 FtM 跨性别者中的研究相对较少。我们的研究旨在确定与 transgender 医学中使用睾酮相关的治疗和安全性结果。在 FtM 跨性别者中，雄激素可有效降低语音频率，增加面部毛发生长，并将红细胞压积和血红蛋白水平提高至成年男性参考范围。与顺性别女性相比，据回顾性报告心肌梗死的发生率高 1.2 倍至 3.7 倍。血压、血糖控制和体重指数在 FtM 跨性别者中保持不变。雄激素在 FtM 跨性别者中有重要的心血管代谢影响。随机对照试验、更长的随访期和涉及老年人的研究可能会进一步改善 FtM 跨性别者的管理。
